Parvus Therapeutics, Calgary Canada/San Francisco, CA selects the Domann Organization to recruit a Chief Development Officer and Head, CMC as the company announces an Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes